✦ LIBER ✦

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)

✍ Scribed by Schnabel, Philipp A.; Smit, Egbert; Carpeo, Javier de Castro; Leniewski-Kmak, Krzysztof; Aerts, Joachim; Kraaij, Kees; Visseren-Grul, Carla; Dyachkova, Yulia; Taipale, Kaisa; Girvan, Allicia; Moro-Sibilot, Denis

Book ID: 118011484
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 217 KB
Volume: 78
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.09.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advanced non-small cell lung cancer mana

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

✍ Gridelli, Cesare; de Marinis, Filippo; Ardizzoni, Andrea; Novello, Silvia; Fonta 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 345 KB

Influence of histological type, smoking

Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer

✍ Toru Itaya; Nobuyuki Yamaoto; Masahiko Ando; Masako Ebisawa; Yukiko Nakamura; Ha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB

PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN

PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)

✍ C Chouaid; H Lecaer; J Crequit; I Monnet; S Chouabe; C Locher; D Paillotin; JB A 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN79 Cost Effectiveness of Erlotinib in

PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

✍ Chouaid, C.; Le Caer, H.; Corre, R.; Crequit, J.; Jullian, H.; Falchero, L.; Duj 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

An International, Multicenter, Randomize

An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial

✍ Cesare Gridelli; Charles Butts; Fortunato Ciardiello; Ronald Feld; Ciro Gallo; F 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 91 KB

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB